Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07457515

Breastmilk and the Link to Overweight/Obesity and Maternal Diet in the Mother-breastmilk-child Triad

The prospective 5-month follow-up study will involve 150 mother-infant dyads grouped based on maternal baseline BMI category (normal weight, overweight, obesity). The investigators plan 3 study visits (1, 3, and 6 months postpartum) with analysis the following parameters and outcomes:

1. maternal anthropometry and body composition; 2. maternal dietary intake and dietary patterns (with results of biomarker-based validation); 3. maternal status of lipophilic antioxidants, selected vitamins, and fatty acids profile that may be related to adipose tissue metabolism, inflammation, and cardiometabolic status; 4. maternal metabolomics, adipokines, insulin, selected biomarkers of inflammation, altered glucose metabolism, and oxidation; 5. breastmilk composition assessed by systemic approach (macronutrients, fatty acids profile, lipophilic antioxidants, adipokines, hormones, immunological profile, and preliminary lipidomic analysis in part of the study group); 6. infant growth trajectory, body composition, urine metabolomics, and biomarkers of oxidative stress.

Additionally, maternal and infant stool, buccal swabs, and human milk samples will be banked for further microbiome analysis studies.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

19 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Food, Nutrition and Health, Uviversity of British Columbia; Affiliated Investigator, Healthy Starts, BC Children's Hospital Research Institute & Women's Health Research Institute, Vancouver, British Columbia, Canada

Loading trial locations.

About this study

The global obesity pandemic continues to escalate, with projections showing 1 in 5 women and 1 in 7 men obese by 2030. Maternal obesity raises the risk of childhood obesity by 264%, and overweight/obese children are more prone to become obese adults.

Obesity-associated metabolic dysfunctions (inflammation, insulin resistance, dyslipidemia) heighten morbidity and mortality risks. Breastfeeding mitigates overweight/obesity risks, yet mothers with overweight/obesity often encounter challenges in initiation, continuation, and altered milk composition, showing elevated levels of leptin, insulin, and n-6/n-3 fatty acids. However, findings on other components, like total fat, fatty acids, insulin, adipokines, carotenoids, and immune factors, remain inconsistent due to methodological limitations and lack of comprehensive analysis. Nonetheless, the potential pro-inflammatory and obesogenic properties of milk produced by mothers with overweight/obesity have been discussed. Recent systematic reviews link breastmilk protein, fat, leptin, and IL-6 to infant growth and adiposity. Findings for other components remain unclear due to small samples, methodological limitations, and lack of a systemic approach to analyze breastmilk as a complex biological system. Alterations in breastmilk composition may stem from disrupted de novo synthesis, transport across the blood-breastmilk barrier, or altered circulating levels. Recent studies showed impaired de novo synthesis of C15:0 and C16:1 fatty acids, probably caused by insulin resistance and reduced long-chain fatty acid transfer linked to inflammation (suppress lipoprotein lipase activity essential for transporting lipid compounds). Hence, poor cardiometabolic status may mediate altered breastfeeding outcomes and milk composition, but it requires further studies. Studies among non-lactating individuals suggested lifestyle and diet play crucial roles in mitigating overweight/obesity metabolic implications (e.g., metabolically healthy obese (MHO) and metabolically obese with normal weight (MONW) phenotypes). Maternal diet can influence breastmilk concentration of certain diet-dependent nutrients and bioactives (e.g., fatty acids, vitamins A, D, and carotenoids). Similarly, prohealthy/unhealthy dietary patterns seem to have beneficial/unfavorable effects on breastmilk composition and breastfeeding outcomes, but results remain inconclusive. Nonetheless, some suggest that diet may mitigate the effects of maternal overweight/obesity on breastmilk composition in mothers with overweight/obesity. The mechanisms linking obesity-related changes in breastmilk to infant development remain unclear. This study addresses this gap by studying the mother-breastmilk-infant triad, focusing on maternal cardiometabolic status, diet, breastmilk composition as a complex biological system, and anthropometric and metabolic outcomes.

This study aims to elucidate the intricate interplay between maternal adiposity, cardiometabolic status, diet, and breastmilk composition and to understand the role of breastmilk in the transmission of obesity and the shaping of infant metabolic health.

Our research questions will aim to determine/explore the following questions:

Q1. How does the maternal BMI category differentiate breastmilk composition from a systemic perspective? Q2. How does maternal cardiometabolic status mediate OW/OB-related alterations in breastmilk composition? Q3. Whether (and how) maternal diet moderates OW/OB-related alterations in breastmilk composition? Q4. Whether (and how) maternal OW/OB differentiates infant metabolomic profile? Q5. Whether (and how) OW/OB-related alterations in breastmilk composition influence infant outcomes and obesity risk? Q6. Whether (and how) maternal dietary patterns moderate adverse health outcomes of maternal OW/OB in infants?

The research hypotheses assume that:

H1. Maternal OW and OB are associated with pro-inflammatory properties and altered breastmilk metabolome via obesity-related low-grade inflammation, metabolic alterations, and oxidative stress, not dietary differences.

H2. Metabolically healthy OW and OB mothers produce less altered breastmilk than metabolically unhealthy mothers, as cardiometabolic status mediates between adiposity and breastmilk composition.

H3. A pro-healthy dietary pattern attenuates, and a westernized dietary pattern exacerbates obesity-related alterations in breastmilk composition due to differences in concentrations of pro-, anti-inflammatory, and antioxidant dietary compounds.

H4. Infants of OW and OB mothers have altered growth trajectories and metabolic pathways, higher fat mass, and oxidative stress compared to infants of NW mothers.

H5. Obesity-related changes in breastmilk composition determine alterations in infant outcomes.

H6. Maternal pro-health/westernized dietary patterns and metabolic health mitigate/exacerbate the adverse effects of overweight and obesity on infant outcomes.

The investigators will verify these hypotheses based on results collected using gold standards and novel body composition assessment and analytical methods (DXA scans, HPLC, GC-MS, ELISA, and LC-MS), nutrient-based and dietary pattern-based dietary assessment with biomarkers validation, in-depth evaluation of maternal cardiometabolic status and infant outcomes, and a systemic approach to breastmilk composition analysis. The findings will lay the foundation for tailored, evidence-based interventions to disrupt the intergenerational transmission of obesity. Furthermore. contribute to advancing the health sciences discipline and decreasing the global health burden of overweight and obesity, supporting the realization of WHO's Global Nutrition Goals.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for mother:

  • at least 19 years,
  • plan of exclusively or predominantly breastfeeding for 6 months,
  • consent to a sampling of biological material and participate in all planned procedures (for both mother and infant),
  • willingness to finish the follow-up,
  • well-understanding of the Polish language (for non-Polish nationalities); for infants:
  • 1 month or less,
  • clinically healthy,
  • none or one formula feeding per day

Exclusion criteria

for mother:

  • type 1 or 2 diabetes diagnosed before pregnancy,
  • uncontrolled thyroid disease,
  • breastfeeding more than 1 child or being a milk donor,
  • tobacco/alcohol use during pregnancy or currently,
  • inability to express a sufficient amount of milk; for infants:
  • congenital disease,
  • birth from a multiple pregnancy,
  • preterm birth (<37 Hbd).

Treatment and study plan

Primary outcomes

  1. Difference between groups and change from 1 to 6 months postpartum in maternal body fat percentage

    Time frame: 1, 3, and 6 months postpartum

    Assessment of changes in total body fat content, assessed by a bioelectrical impedance analysis (BIA) and a dual-energy X-ray absorptiometer (DXA). Results will be reported as a percentage (%).

  2. Difference between groups and change from 1 to 6 months postpartum in maternal fat-free mass percentage

    Time frame: 1, 3, and 6 months postpartum

    Assessment of changes in fat-free mass, assessed by a bioelectrical impedance analysis (BIA) and a dual-energy X-ray absorptiometer (DXA). Results will be reported as a percentage (%).

  3. Difference between groups and change from 1 to 6 months postpartum in maternal Visceral Fat Area

    Time frame: 1, 3, and 6 months postpartum

    Assessment of changes in visceral fat area, assessed by DXA. Results will be reported as square centimeters (cm^2).

  4. Difference between groups and change from 1 to 6 months postpartum in maternal Subcutaneous Fat Area

    Time frame: 1, 3, and 6 months postpartum

    Assessment of changes in subcutaneous fat area, assessed by DXA. Results will be reported as square centimeters (cm^2).

  5. Difference between groups and change from 1 to 6 months postpartum in maternal Body Mass Index (BMI)

    Time frame: 1, 3, and 6 months postpartum

    Weight and height will be combined to report BMI in kg/m^2.

  6. Difference between groups and change from 1 to 6 months postpartum in maternal Waist-Hip Ratio (WHR)

    Time frame: 1, 3, and 6 months postpartum

    Assessment of fat distribution calculated as the waist measurement divided by the hip measurement (dimensionless ratio).

  7. Difference between groups and change from 1 to 6 months postpartum in maternal Waist-to-Height Ratio (WHtR)

    Time frame: 1, 3, and 6 months postpartum

    Assessment of fat distribution calculated as the waist measurement divided by height (dimensionless ratio).

  8. Difference between groups and change from 1 to 6 months postpartum in metabolic syndrome (MetS) incidence

    Time frame: 1, 3, 6 months postpartum

    Assessment of MetS incidences diagnosed based on the occurence of three from five metabolic abnormalities diagnosed based on International Diabetes Federation-established cut-off points for women for waist circumference (≥80 cm), fasting blood glucose (≥100 mg/dL), triglicerides (≥150 mg/dL), HDL cholesterol (<50 mg/dL), blood pressure (systolic SBP ≥ 130 or diastolic ≥ 85 mmHg) as a marker of cardiometabolic health.

  9. Difference between groups and change from 1 to 6 months postpartum in maternal glycated haemoglobin (HbA1c)

    Time frame: 1, 3, 6 months postpartum

    Assessment of changes in HbA1c (reported in %) as a marker of maternal cardiometabolic health.

  10. Difference between groups and change from 1 to 6 months postpartum in Homeostatic Model Assessment - Insulin Resistance (HOMA-IR)

    Time frame: 1, 3, 6 months postpartum

    Assessment of HOMA-IR calculated as the product of fasting insulin [µIU/mL] and fasting glucose [µIU/mL] divided by 22.5 (dimensionless ratio) as an indicator of maternal cardiometabolic health.

  11. Difference between groups and change from 1 to 6 months postpartum in maternal serum leptin

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal serum leptin assessed by the ELISA method as an indicator of maternal cardiometabolic health.

  12. Difference between groups and change from 1 to 6 months postpartum in maternal serum adiponectin

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal serum adiponectin assessed by the ELISA method as an indicator of maternal cardiometabolic health.

  13. Difference between groups and change from 1 to 6 months postpartum in maternal serum and infant urine Retinol-Binding Protein-4 (RBP4)

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal serum and infant urine RBP-4 assessed by the ELISA method as an indicator of maternal and infant cardiometabolic health.

  14. Difference between groups and change from 1 to 6 months postpartum in human milk macronutrients

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk macronutrients (fat, carbohydrate, dry material, protein, true protein) concentration assessed by mid-infrared (mid-IR) transmission spectroscopy method. Results will be reported in grams per 100 mL.

  15. Difference between groups and change from 1 to 6 months postpartum in human milk energy value

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk energy value assessed by mid-infrared (mid-IR) transmission spectroscopy method. Results will be reported in kcal per 100 mL.

  16. Difference between groups and change from 1 to 6 months postpartum in human milk secretory immunoglobulin A (S-IgA)

    Time frame: 1, 3, and 6 months postpartum

    Assessment of human milk S-IgA assessed by Enzyme-Linked Immunosorbent Assay (ELISA) method. Results will be reported in grams per liter [g/L].

  17. Difference between groups and change from 1 to 6 months postpartum in human milk lactoferrin

    Time frame: 1, 3, and 6 months postpartum

    Assessment of human milk lactoferrin assessed by ELISA method. Results will be reported in grams per liter [g/L].

  18. Difference between groups and change from 1 to 6 months postpartum in human milk leptin

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk leptin assessed by ELISA method.

  19. Difference between groups and change from 1 to 6 months postpartum in human milk adiponectin

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk adiponectin assessed by ELISA method.

  20. Difference between groups and change from 1 to 6 months postpartum in human milk insulin

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk insulin assessed by ELISA method.

  21. Difference between groups and change from 1 to 6 months postpartum in human milk High-Sensitivity C-Reactive Protein (hs-CRP)

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk hsCRP assessed by ELISA method.

  22. Difference between groups and change from 1 to 6 months postpartum in human milk interleukin 1 (IL-1)

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk IL-1 assessed by ELISA method.

  23. Difference between groups and change from 1 to 6 months postpartum in human milk interleukin 6 (IL-6)

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk IL-6 assessed by ELISA method.

  24. Difference between groups and change from 1 to 6 months postpartum in human milk Tumor Necrosis Factor-alpha (TNF-alfa)

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk TNF-alfa assessed by ELISA method.

  25. Difference between groups and change from 1 to 6 months postpartum in human milk fatty acid profile

    Time frame: 1, 3, 6 months of postpartum

    Assessment of human milk fatty acid profile analyzed as methyl ester (FAME) by gas chromatography. Results will be reported as concentration within a total fat [% wt/wt].

  26. Difference between groups and the change from 1 to 6 months of life in infant anthropometric development

    Time frame: 1, 3, 6 months of life

    Assessment of anthropometric development calculated as weight-, length-, BMI-, and head circumference z-scores for age and sex, analyzed based on WHO standards.

  27. Difference between groups and the change from 1 to 6 months of life in infant body fat-free mass percentage

    Time frame: 1, 6 months of life

    Assessment of changes in total body fat-free mass content, assessed by the whole-body DXA scans with a vacuum cushion to prevent movement. Results will be reported as a percentage (%).

  28. Difference between groups and the change from 1 to 6 months of life in infant body fat percentage

    Time frame: 1, 6 months of life

    Assessment of changes in total body fat content, assessed by the whole-body DXA scans with a vacuum cushion to prevent movement. Results will be reported as a percentage (%).

Secondary outcomes

  1. Difference between groups and the change from 1 to 6 months postpartum in the maternal resting metabolic rate (RMR)

    Time frame: 1, 3, 6 months postpartum

    Assessment of the rate of maternal energy metabolism assessed by indirect calorimetry. Results will be reported as kilocalories per day [kcal/d].

  2. Difference between groups and the change from 1 to 6 months postpartum in maternal dietary intake

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal dietary intake using 3-day food records.

  3. Difference between groups and the change from 1 to 6 months postpartum in maternal dietary habits

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal dietary intake using a food frequency questionnaire (FFQ).

  4. Difference between groups and change from 1 to 6 months postpartum in maternal short- and long-term fatty acid status

    Time frame: 1, 3, 6 months postpartum

    Assessment of serum blood and erythrocyte membranes fatty acids profile analyzed by gas chromatography. Results will be reported as concentration within a total fat [% wt/wt].

  5. Difference between groups and change from 1 to 6 months postpartum in maternal and human milk lipophilic antioxidants and vitamins

    Time frame: 1, 3, 6 months postpartum

    Assessment of plasma and human milk carotenoids, retinol, and vitamin E, as well as serum vitamin D (25(OH)D) analyzed by high-performance liquid chromatography (HPLC). Results will be reported as micromoles per liter [µmol/L].

  6. Difference between groups and the change from 1 to 6 months of life in infant skin carotenoid status

    Time frame: 1, 3, 6 months of life

    Assessment of skin carotenoids assessed by reflectance spectroscopy with Veggie Meter (Longevity Link, Ltd.). Results will be reported as a skin carotenoid score (SCS; 0-800, higher values mean more carotenoids)

  7. Difference between groups and change from 1 to 6 months postpartum in maternal and infant urine 8-isoprostane

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal and infant urine 8-isoprostane analyzed by the ELISA as an indicator of oxidative stress. Results will be reported as picograms per milligram of creatinine [pg per mg of creatinine].

  8. Difference between groups and change from 1 to 6 months postpartum in maternal serum hsCRP

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal serum hsCRP assessed by the ELISA method as an indicator of systemic inflammation.

  9. Difference between groups and change from 1 to 6 months postpartum in maternal serum IL-1

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal serum IL-1 assessed by the ELISA method as an indicator of systemic inflammation.

  10. Difference between groups and change from 1 to 6 months postpartum in maternal serum IL-6

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal serum IL-6 assessed by the ELISA method as an indicator of systemic inflammation.

  11. Difference between groups and change from 1 to 6 months postpartum in maternal serum TNF-alfa

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal serum TNF-alfa assessed by the ELISA method as an indicator of systemic inflammation.

  12. Difference between groups and change from 1 to 3 months postpartum in human milk lipidomics

    Time frame: 1, 3 months postpartum

    Assessment of human milk triacylglycerols (TG), diacylglycerols (DG), phosphatidylcholine (PC), sphingomyelin (SM), and phosphatidylethanolamine (PE) assessed by targeted lipidomic analysis using the LC-MS. Results expressed as the percentage relative amount of many lipid species.

  13. Difference between groups and change from 1 to 6 months postpartum in metabolomic profile of maternal serum blood and infant urine

    Time frame: 1, 3, 6 months postpartum

    Assessment of the serum and urine non-targeted metabolomic profiles.

Other outcomes

  1. Difference between groups and change from 1 to 6 months postpartum in Bone Mineral Density (BMD)

    Time frame: 1, 3, 6 months postpartum

    Assessment of changes in bone mineral density (BMD) using DXA.

  2. Difference between groups and change from 1 to 6 months postpartum in maternal hydration status

    Time frame: 1, 3, 6 months postpartum

    Assessment of changes in hydration status, assessed by urine osmolality [mOsm/kg].

  3. Difference between groups and change from 1 to 6 months postpartum in maternal well-being

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal well-being assessed using the WHO-5 Well-being Index. Results will be expressed as a percentage score from 0 to 100, with a higher score indicating a better quality of life.

  4. Difference between groups and change from 1 to 6 months postpartum in maternal fatigue

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal fatigue using the Fatigue Assessment Scale (FAS). Results will be expressed as a FAS score ranging from 10 to 50, with higher scores indicating more severe fatigue.

  5. Difference between groups and change from 1 to 6 months postpartum in maternal perceived stress

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal perceived stress assessed by the Perceived Stress Scale (PSS-10). Results will be expressed as a PSS-10 score ranging from 0 to 40, with higher scores indicating greater perceived stress.

  6. Difference between groups and change from 1 to 6 months postpartum in maternal postpartum depression

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal postpartum depression risk assessed by the Edinburgh Postnatal Depression Scale (EPDS). Results will be expressed as an EPDS score ranging from 0 to 30, with higher scores indicating greater risk of postpartum depression, and values >=13 indicate probable depression.

  7. Difference between groups and change from 1 to 6 months postpartum in maternal breastfeeding self-efficacy

    Time frame: 1, 3, 6 months postpartum

    Assessment of maternal breastfeeding self-efficacy assessed by the Breastfeeding Self-Efficacy Scale (BSES-SF). Results will be reported as a BSES-SF score ranging from 14 to 70, with higher scores indicating greater confidence in breastfeeding.

Study contacts

Contact information is provided by the study sponsor or research team.

Jadwiga Hamulka, Professor

CONTACT

[email protected]

+48225937122

Monika A. Zielinska-Pukos, PhD

CONTACT

[email protected]

+48225937125

Sponsors and collaborators

Lead sponsor

Warsaw University of Life Sciences

Other

Collaborators

  • National Institute of Public Health, National Research Institute, Poland
  • National Science Centre, Poland
  • Wroclaw Medical University

Registry information

Official study title

Analysis of the Transmission of Overweight/Obesity in the Mother-breastmilk-child Triad in Relation to Maternal Cardiometabolic Status and Diet

Acronym: BLOOM-Triad

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Mar 9, 2026
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.